Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer
August 15 2022 - 4:57PM
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”),
a biopharmaceutical company focused on developing a diversified
pipeline of targeted therapeutic candidates across multiple
modalities for patients with cancer, today announced that Jacquelyn
(Jackie) Sumer, J.D., will join the company as Chief Legal Officer.
Jackie brings with her nearly two decades of legal and strategic
leadership experience, with proven skills in navigating legal and
compliance issues through clinical development and
commercialization of cancer therapies.
“The appointment of Jackie as Chief Legal
Officer brings her exceptional expertise and legal guidance as
our portfolio advances and Cullinan Oncology continues to grow as a
late-stage oncology company,” said Nadim Ahmed, Chief Executive
Officer of Cullinan Oncology. “With our dedication to creating new
standards of care for patients with cancer, and through her
extensive development and commercialization legal experience,
Jackie will be an important addition to our leadership team.”
In her most recent role, Jackie served as Chief Legal and
Compliance Officer at Genocea Biosciences. Prior to that, Jackie
was Vice President, Assistant General Counsel at Bristol Myers
Squibb, where she led the Worldwide Hematology and Cell Therapy
Legal team, following a role as head of Celgene Corporation’s CAR T
legal team. Jackie began her legal career at Kaye Scholer, LLP, and
clerked for the Honorable Gladys Kessler at the United States
District Court in Washington, D.C. She holds a J.D. and a Master of
Laws in international and comparative law from Duke University
School of Law and a B.A. from Bucknell University.
In connection with her appointment as Chief Legal Officer, the
compensation committee of Cullinan Oncology’s Board of Directors
granted Ms. Sumer a stock option award to purchase 190,000 shares
of its common stock outside of the Cullinan Oncology, Inc. 2021
Stock Option and Incentive Plan. The stock option award was granted
as an inducement material to Jackie entering into employment with
Cullinan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The option has an exercise price of $14.16, which is equal to
the closing price of Cullinan Oncology’s common stock on August 15,
2022. The option has a ten-year term and vests over four years,
with 25 percent of the original number of shares underlying the
option vesting on the one-year anniversary of the vesting
commencement date and then in equal installments for 36 months
thereafter, subject to Ms. Sumer’s continued service with Cullinan
through the applicable vesting dates.About Cullinan
OncologyCullinan Oncology, Inc. (Nasdaq: CGEM) is a
biopharmaceutical company dedicated to creating new standards of
care for patients with cancer. We innovate without borders to find
the most promising clinic-ready cancer therapies, whether from our
own discovery efforts or through exceptional engagement with our
academic and industry partners. Anchored in a deep understanding of
immuno-oncology and translational cancer medicine, we leverage our
scientific excellence in small molecules and biologics to create
differentiated ideas, identify unique targets, and select the
optimal modality to develop transformative therapeutics across
cancer indications. Powered by our novel research model, we push
conventional boundaries from candidate selection to cancer
therapeutic, applying rigorous early experimentation to fast-track
only the most promising assets to the clinic and ultimately
commercialization. As a result, our diversified pipeline is
strategically built with assets that activate the immune system or
inhibit key oncogenic drivers across a wide range of modalities,
each with the potential to be the best or first in their class. Our
people possess deep scientific expertise, seek innovation openly,
and exercise creativity and urgency to deliver on our promise to
bring new therapeutic solutions to patients with cancer. Learn more
about our Company at www.cullinanoncology.com, and follow us
on LinkedIn and Twitter.
ContactsInvestor RelationsChad Messer+1
203.464.8900cmesser@cullinanoncology.com
MediaRose Weldon+1 215.801.7644rweldon@cullinanoncology.com
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jul 2023 to Jul 2024